One of the most important factors that saved countless lives during the pandemic was all the institutions coming together to address the problem.
But has it left us better prepared for Disease X?
Watch the full podcast here: https://t.co/9GtRo00MY8
India had an estimated 115.1 million people living with chronic kidney disease in 2017, highlighting the urgent need for accessible and timely kidney function testing.
Source: Global Burden of Disease Study, published in PubMed Central
https://t.co/v7BKo6SRai
Early detection can help prevent or slow further kidney damage, yet conventional creatinine testing depends on pathology labs, creating delays and limiting screening, especially in underserved areas.
Supported by BFI-BIOME, Utopic Tech is changing that with Creasens, a portable point-of-care device designed to bring kidney-function assessment closer to the patient.
Creasens need just 10 µL of blood from a finger prick to measure creatinine, a key marker used to assess kidney function. The device then uses the creatinine result, along with age and gender, to calculate eGFR (estimated glomerular filtration rate), a measure of how effectively the kidneys are filtering waste from the blood. Results are generated in just 3 minutes.
At its core, Creasens uses a biosensing-based measurement system to detect creatinine in the blood and convert that biological signal into a quantitative result. Its compact, portable design means testing can move beyond centralized laboratories to clinics, hospitals, screening camps and rural healthcare settings. Utopic Tech’s validation study reports 97% overall diagnostic accuracy compared with a central laboratory reference method.
The potential impact is significant: less waiting, fewer barriers to testing and more opportunities to identify kidney problems earlier, particularly in communities where access to laboratory diagnostics is limited.